Request Demo
Last update 08 May 2025
Aegros Ltd.
Last update 08 May 2025
Overview
Related
ACTRN12620001249943
Intravenous immunoglobulin rich in neutralising antibodies to SARS-CoV-2 as a passiveimmunity modality in healthy individuals : an open label, active control Phase 1/2 Study to investigate the safety profile and to characterise the pharmacokinetics of COVID-19 convalescent plasma and hyperimmune intravenous immunoglobulin G specific to SARS-CoV-2.
100 Clinical Results associated with Aegros Ltd.
Login to view more data
Login to view more data
100 Deals associated with Aegros Ltd.
Login to view more data
100 Translational Medicine associated with Aegros Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 08 Aug 2025
No data posted
Login to keep update
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free